Pfizer (NYSE:PFE) Announces Earnings Results

Pfizer (NYSE:PFE) announced its earnings results on Tuesday. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.68 by $0.09, FiscalAI reports. The firm had revenue of $15.03 billion during the quarter, compared to analyst estimates of $14.40 billion. Pfizer had a return on equity of 19.38% and a net margin of 6.80%.The business’s revenue was up 2.6% compared to the same quarter last year. During the same period last year, the firm posted $0.78 EPS. Pfizer updated its FY 2026 guidance to 2.800-3.000 EPS.

Here are the key takeaways from Pfizer’s conference call:

• Positive Sentiment: Pfizer raised its 2026 revenue guidance midpoint by $500 million to $60.5–$62.5 billion, despite lowering expected COVID revenue to approximately $4 billion. Adjusted EPS guidance was reaffirmed at $2.80–$3.00, absorbing an estimated $0.10 impact from the Innovent transaction.
• Positive Sentiment: The non-COVID business performed strongly, with underlying revenue up 5% operationally and launched and acquired products up 27% excluding prior-year one-time items. Key contributors included Eliquis, Padcev, Vyndaqel, Lorbrena, and Nurtec, while Padcev revenue grew more than 20% following its expanded bladder-cancer indication.
• Positive Sentiment: Pfizer expanded its cost-reduction targets, now expecting approximately $9.7 billion in total net savings through 2029, including additional savings from technology, simplification, and manufacturing optimization. Management said these efforts should support margin expansion while preserving investment in R&D and the dividend.
• Negative Sentiment: The Phase III study of the Seagen-derived SV lung-cancer therapy failed to meet its primary overall-survival endpoint in the overall population, although Pfizer highlighted a benefit in patients who received only one prior line of therapy. The result, along with the removal of Vabryda revenue projections, contributed to $4.3 billion in non-cash intangible-asset impairments and creates additional execution risk for the oncology pipeline.
• Neutral Sentiment: Pfizer emphasized potentially important longer-term catalysts, including its obesity programs, with 10 planned Phase III studies for berobenatide/nirubenatide-related therapies and an initial approval target beginning in 2028. Management also expects multiple regulatory decisions, data readouts, and pivotal study starts over the next 12 months, but these programs remain subject to clinical and regulatory risk.

Pfizer Stock Performance

Shares of Pfizer stock traded up $0.09 during trading hours on Thursday, reaching $25.89. The company had a trading volume of 19,590,655 shares, compared to its average volume of 42,270,738. The firm has a market cap of $147.59 billion, a PE ratio of 34.05 and a beta of 0.34. Pfizer has a one year low of $23.58 and a one year high of $28.75. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94. The business has a fifty day simple moving average of $25.01 and a 200 day simple moving average of $26.16.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.6%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s dividend payout ratio (DPR) is presently 226.32%.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer exceeded second-quarter earnings and revenue expectations, supported by strong demand for the blood thinner Eliquis and growth from newer and acquired products. The company raised the low end of its 2026 revenue outlook, with guidance reaching as high as $62.5 billion. Pfizer beats quarterly profit estimates on strong demand for blood thinner Eliquis
• Positive Sentiment: Management identified continued non-COVID growth, deeper cost reductions and pipeline catalysts as key recovery drivers. Pfizer is targeting an additional $2.5 billion in savings, which could support margins and earnings over time. Pfizer Q2 Earnings Call Highlights Non-COVID Growth and Cost Cuts
• Positive Sentiment: A positive Phase 3 readout for Litfulo in vitiligo adds a potential new indication for Pfizer’s commercial portfolio and supports the company’s effort to diversify beyond COVID products. Pfizer Reports Positive Phase 3 LITFULO Data In Vitiligo
• Neutral Sentiment: Investor attention remains focused on Pfizer’s obesity-drug program. Upcoming data could become a significant catalyst, but recent setbacks and uncertainty over the candidate’s competitiveness temper enthusiasm. Pfizer Ducks Continued Covid Fallout As Hard-Fought Obesity Readout Looms
• Negative Sentiment: COVID-related revenue remains under severe pressure, including a reported 95% plunge in sales of Pfizer’s COVID antiviral. Patent expirations, a reported quarterly net loss and noncash impairments also keep longer-term growth and pipeline execution concerns in focus. Pfizer Covid Pill Revenue Plunges 95%. The Stock Is Rising Anyway.

Analyst Ratings Changes

A number of analysts recently issued reports on the stock. Royal Bank Of Canada upgraded shares of Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price objective for the company in a report on Tuesday, June 9th. Morgan Stanley increased their target price on shares of Pfizer from $27.00 to $28.00 and gave the company an “equal weight” rating in a research report on Friday, April 10th. Wolfe Research restated an “underperform” rating and set a $26.00 price target on shares of Pfizer in a research note on Thursday, May 14th. CICC Research initiated coverage on Pfizer in a research note on Thursday, April 16th. They issued an “outperform” rating and a $33.00 price objective on the stock. Finally, UBS Group reissued a “neutral” rating and set a $27.00 price objective on shares of Pfizer in a report on Wednesday, May 27th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, Pfizer presently has a consensus rating of “Hold” and an average price target of $28.50.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Darwin Wealth Management LLC purchased a new position in Pfizer during the second quarter valued at approximately $32,000. IFC & Insurance Marketing Inc. bought a new position in shares of Pfizer in the fourth quarter worth $34,000. Birchwood Financial Partners Inc. purchased a new stake in shares of Pfizer in the fourth quarter worth $38,000. WFA of San Diego LLC bought a new stake in Pfizer during the second quarter valued at $40,000. Finally, Atlas Capital Advisors Inc. purchased a new position in Pfizer during the fourth quarter worth about $41,000. Institutional investors own 68.36% of the company’s stock.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.